tryptoline has been researched along with monorden in 2 studies
| Studies (tryptoline) | Trials (tryptoline) | Recent Studies (post-2010) (tryptoline) | Studies (monorden) | Trials (monorden) | Recent Studies (post-2010) (monorden) |
|---|---|---|---|---|---|
| 222 | 1 | 69 | 341 | 0 | 99 |
| Protein | Taxonomy | tryptoline (IC50) | monorden (IC50) |
|---|---|---|---|
| Chain A [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1 | Homo sapiens (human) | 400 | |
| Chain A [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 3 | Homo sapiens (human) | 400 | |
| ATP-dependent molecular chaperone HSP82 | Saccharomyces cerevisiae S288C | 0.1193 | |
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | 0.2092 | |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | 0.1148 | |
| ATP-dependent molecular chaperone HSC82 | Saccharomyces cerevisiae S288C | 0.2 | |
| Carbonyl reductase [NADPH] 1 | Homo sapiens (human) | 3.27 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.027 | |
| Proto-oncogene tyrosine-protein kinase Src | Rattus norvegicus (Norway rat) | 0.18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Fallarero, A; Hanski, L; Isojärvi, J; Karhu, E; Vuorela, P | 1 |
2 other study(ies) available for tryptoline and monorden
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy.
Topics: Anti-Bacterial Agents; Azithromycin; Biological Products; Cell Line; Cell Survival; Chlamydophila pneumoniae; Drug Discovery; Humans; Ligands; Microbial Sensitivity Tests; Molecular Structure | 2017 |